QualityDipStocks / Consumer Discretionary · Specialty Chemicals
Clorox Company CLX
Outside our quality screen, so we don’t track its dips. It’s 31% below its 52-week high.
Outside our quality screen, trading well above our fair value estimate, 4% under its Market Value.
- Fair value est.
- $49.44−44%
- Market Value
- $92.00price −4%
- Off 52-wk high
- −31%
- Risk vs market
- Lowbeta 0.31
4 bullish · 5 bearish See why
Key levels
Every level vs today’s $88.00
- Fair value est.base case$49.44−43.8%
- 52-wk lowlowest close, 1 year$80.41−8.6%
- PriceFri Oct 30 close$88.00you are here
- Market Valueavg paid since Aug 3$92.00+4.5%
- 52-wk highhighest close, 1 year$127.16+44.5%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is above even the bull case.
What the price implies To be worth today’s price, CLX’s free cash flow would need to grow about 13% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much CLX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 2.5× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.31
- Volatility
- 32% vs 13% SPY
- Correlation SPY
- 0.12
- Correlation QQQ
- −0.04
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
Cash returnsDividend yield of 5.6% ($602M paid over 12 months).
ValuationP/E of 18.3×, below the 20.9× median for the 169 Consumer Discretionary companies we cover.
ProfitabilityGross margin of 42%, above the 39% median for the 120 Consumer Discretionary companies we cover.
ValuationTrades 4.3% below its Market Value of $92.00, the average price paid since the Aug 3 filing.
Top bearish points 5 of 5
ValuationOur DCF fair value estimate is $49.44, 44% below the price.
Balance sheetDebt rose 104% to $5.1B from FY2024 to FY2026.
Cash returnsFree cash flow fell 47% over the last 12 months vs the 12 months before.
Balance sheetNet debt of $4.9B, 46% of the market cap (Jun 30, 2026).
QualityDoesn’t pass our quality screen: sales down vs the year-ago quarter; net debt 4.8× EBITDA (limit 3×).
Who’s talking about it
Notable investors, executives, analysts and public figures on Clorox Company in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Consumer Discretionary
All fundamentals
P/E 18.3 · FCF yield 3.8% · Sales −5%
Valuation
- P/E
- 18.3×Consumer Discretionary median 20.9×
- Price / FCF
- 26.5×
- FCF yield
- 3.8%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 1.59×
- Price / book
- 119.08×
- Market cap
- $10.7Bprice × diluted shares
- Enterprise value
- $15.6B
Growth
- Revenue, 12 months
- $6.7B
- Sales growth, 12 months
- −5.4%vs the 12 months before
- Sales growth, 3 yrs
- −3.1%/yrfrom FY2023
- Diluted EPS, 12 months
- $4.81
- EPS growth, last FY
- −26.2%
- Net income, 12 months
- $587M
- Net income growth
- −28%12 months vs before
Profitability
- Gross margin
- 42.3%
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- 8.7%
- FCF margin
- 6.0%
- Return on equity
- n/an/m: very small or negative equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $143M
- Total debt
- $5.1B
- Net cash
- −$4.9B
- Debt / equity
- n/an/m: equity near zero
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $405M
- FCF growth, 12 months
- −47%
- Dividend yield
- 5.62%$602M paid
- Payout ratio
- 103%
- Buybacks, 12 months
- $256M2.4% of market cap
- Share count, 1 year
- −1.8%diluted shares vs a year ago
- Stock-based comp
- $48M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Clorox Company’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $49.44 · MV $92.00 · FCF value $22.62
Assumes 3.0% growth for 5 years (revenue grew -0.0% a year FY22–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $3.12 a share (trailing 12 months to Mar 31, 2026), from the 10-Q filed Apr 30, 2026. Net debt $2.9B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 54 · 5 days +1.9%
The business
FCF $0.1B · Sales −2%
- Free cash flow, 12 months$0.1B
- Free-cash-flow yield1.0%
- Free-cash-flow margin2%
- Gross margin42%
- Operating margin13%
- Return on invested capital12%
- Return on equity164%
- Sales growth (latest quarter vs year-ago quarter)−2%
- Net debt / EBITDA4.8×
Next report
Nov 2
- DateMon Nov 2, after the close
- Consensus EPS$0.97
- Year-ago EPS$0.85
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
CLX is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.